Gelfoam to Prevent Pneumothorax After Lung Biopsy

Pneumothorax Iatrogenic Postprocedural Clinical Trial

Official title:

Gelfoam Slurry as an Embolization Agent of the Needle Tract to Prevent Pneumothorax From Percutaneous CT-guided Lung Biopsy: A Randomized Controlled Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03669003
• Other study ID #: 20170830
• Status: Withdrawn
• Phase: Phase 2
• Start date: December 1, 2018
• Est. completion date: December 1, 2019

Study information

• Verified date: April 2019
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lung cancer is the deadliest of all cancers, and its incidence is on the rise. The importance of accurate and efficient lung biopsy without complications will only increase in importance going forward. Pneumothorax is a common complication of CT-guided lung biopsy. The purpose of this study is to assess the efficacy of using Gelfoam slurry in preventing pneumothorax from lung biopsy in a randomized controlled trial. Gelfoam (Pfizer, New York, NY, USA) is gelatin product approved by the Food and Drug Administration (FDA) for hemostasis during various procedures.

In the study group, the needle track will be laced with Gelfoam slurry following biopsy, and will be compared to standard lung biopsy without any other interventions. Both groups will be followed up with chest x-ray for pneumothorax.

Description:

CT-guided percutaneous lung biopsy is an invaluable tool used for the diagnosis of lung cancer. Pneumothorax (PTX) is the most frequent complication of CT-guided percutaneous lung biopsy, with a reported incidence of 9 to 40% and a cumulative average incidence of about 20%. Most of these are managed conservatively and about 7 to 21% will require placement of a chest tube. Several techniques have been used in the past to prevent the development of PTX by sealing the needle tract with various materials (autologous blood, saline, hydrogel, collagen plugs), but literature has shown them to be unreliable, clumsy or costly.

The use of Gelfoam slurry for embolizing the needle tract following biopsy has been identified in a retrospective study as a possible intervention to reduce the occurrence of pneumothorax and/or chest tube placement. Gelfoam (Pfizer, New York, NY, USA) is a gelatin sponge made from bovine corium, which can absorb fluids 40 times its weight and can enlarge by 200% in size. This property allows the material to effectively plug the biopsy track by volumetric expansion, which prevents passage of air from the lung into the pleural cavity and creation of a pneumothorax. Gelfoam is cheap, is readily available both as a sponge and powder and can be easily made into a slurry by mixing with saline. The slurry is semisolid in consistency and can be easily injected through the biopsy cannula into the needle track.

In the experimental group, as the biopsy cannula is withdrawn, Gelfoam will be injected carefully, lacing the needle track. In both groups, immediate post-procedure CT scans and subsequent follow up X-rays 1 and 2 hours post-procedure will be used to monitor for pneumothorax.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 1, 2019
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

To be included in the study, the patient must:

1. Be between the ages of 18-80.

2. Be indicated for CT-guided percutaneous lung biopsy for evaluation of a solitary pulmonary nodule, or other indicated pulmonary lesion(s).

3. Be cooperative.

To be included in the study, the patient must NOT:

1. Have known allergy to porcine collagen (basis of Gelfoam).

2. Have bleeding diatheses defined by the following coagulation indices: International normalized ratio [INR]>1.5 /platelets<50,000/µL.

3. Have had previous pneumonectomy (unless the lesion is pleurally based and accessible without traversing lung tissue.

4. Have suspected hyatid cyst (due to risk of anaphylactic reaction).

5. Have possible pulmonary arteriovenous malformation (AVM), vascular aneurysm, or pulmonary sequestration (intralobar or extralobar).

6. Have a diagnosis of pulmonary hypertension (especially when considering biopsy of a central lesion).

7. Require positive pressure ventilation.

8. Require consent of proxy to participate.

Related Conditions & MeSH terms

• Pneumothorax
• Pneumothorax Iatrogenic Postprocedural

Intervention

Biological:
• Gelfoam slurry
Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.

Procedure:
• CT-guided percutaneous lung biopsy
Biopsy of a lung nodule under CT guidance.

Locations

Country	Name	City	State
United States	Jackson Memorial Hospital	Miami	Florida
United States	University of Miami	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in incidence of pneumothorax	Comparison of the incidence of pneumothorax in participants of standard lung biopsy vs with Gelfoam slurry	2 hours post-procedure
Secondary	Difference in the rate of necessity for chest tube placement post lung biopsy	Comparison of the necessity for chest tube placement in participants of standard lung biopsy vs with Gelfoam slurry	2 hours post-procedure